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The hereditary spastic paraplegias (HSPs) are genetic conditions characterized by distal axonopathy of the
longest corticospinal tract axons, and so their study provides an important opportunity to understand mech-
anisms involved in axonal maintenance and degeneration. A group of HSP genes encode proteins that loca-
lize to endosomes. One of these is NIPA1 (non-imprinted in Prader-Willi/Angelman syndrome 1) and we have
shown recently that its Drosophila homologue spichthyin inhibits bone morphogenic protein (BMP) signal-
ling, although the relevance of this ﬁnding to the mammalian protein was not known. We show here that
mammalian NIPA1 is also an inhibitor of BMP signalling. NIPA1 physically interacts with the type II BMP
receptor (BMPRII) and we demonstrate that this interaction does not require the cytoplasmic tail of
BMPRII. We show that the mechanism by which NIPA1 inhibits BMP signalling involves downregulation of
BMP receptors by promoting their endocytosis and lysosomal degradation. Disease-associated mutant ver-
sions of NIPA1 alter the trafﬁcking of BMPRII and are less efﬁcient at promoting BMPRII degradation than
wild-type NIPA1. In addition, we demonstrate that two other members of the endosomal group of HSP pro-
teins, spastin and spartin, are inhibitors of BMP signalling. Since BMP signalling is important for distal
axonal function, we propose that dysregulation of BMP signalling could be a unifying pathological com-
ponent in this endosomal group of HSPs, and perhaps of importance in other conditions in which distal
axonal degeneration is found.
INTRODUCTION
The hereditary spastic paraplegias (HSPs) are genetic dis-
orders characterized by distal axonopathy involving the
longest axons of the motor neurons of the corticospinal tract
(1–3). Their study provides an opportunity to understand mol-
ecular cellular mechanisms involved in axonal maintenance
and in ‘dying-back’ axonopathy. Since a similar dying-back
axonopathy is seen in some common neurological conditions
(4,5), understanding its cause may have broad clinical
relevance.
Numerous genes mutated in HSPs have been identiﬁed
(2,3,6). An important subgroup of the proteins they encode
localize to the endosomal membrane trafﬁc compartment,
suggesting that the long axons of the corticospinal tract may
be especially vulnerable to endosomal dysfunction. This
endosomal group includes spastin, spartin and NIPA1 (non-
imprinted in Prader-Willi/Angelman syndrome 1), as well as
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Advance Access published on July 20, 2009others including maspardin and spastizin (2,3,7). Mutations in
the spastin gene are the most frequent cause of HSP and in
most cases are likely to act via a haploinsufﬁciency mechan-
ism (8–11). Spastin is a microtubule-severing enzyme and
we have recently shown that it can be recruited to a number
of membrane sites, including endosomes, where it couples
membrane trafﬁc processes to microtubule remodelling (12).
Mutation of the gene encoding spartin causes Troyer syn-
drome, an autosomal recessive HSP ﬁrst identiﬁed in the
Old Order Amish population, where the causative mutation
is a frameshift likely to cause loss of the protein (13,14).
Spartin can be recruited to endosomes, and endogenous
spartin is required for efﬁcient endosomal degradation of the
EGF receptor (15,16).
Mutations in the gene that encodes NIPA1 cause an autoso-
mal dominant HSP (17). All of the disease-causing mutations
reported so far have been missense mutations (18), which
affect the trafﬁcking of the protein through the biosynthetic
pathway by causing its trapping in the endoplasmic reticulum
(19,20). It has been argued, based on data from overexpression
systems in mammalian cells and Caenorhabditis elegans, that
this could cause the disease via a gain-of-function induction of
ER stress and the unfolded protein response (UPR) (19). An
alternative hypothesis arising from our study of spichthyin,
the Drosophila homologue of NIPA1, is that bone morpho-
genic protein (BMP) signalling could be involved, since
spichthyin is an inhibitor of BMP signalling (21).
InDrosophila,enhancedBMPsignallingcausesanabnormal
distal axonal overgrowth phenotype at the presynaptic neuro-
muscular junction (NMJ) (21–23), and indeed larvae lacking
spichthyin have a distal axonal abnormality that includes
synaptic overgrowth at the NMJ (21). The distal axonal pheno-
type seen in ﬂies lacking spichthyin is rescued by genetic
manipulations blocking BMP signalling, indicating that
enhanced BMP signalling is critical to its development. The
observations in the ﬂy system therefore suggest that abnormal
BMP signalling is a potential candidate mechanism by which
abnormality of NIPA1 could cause axonopathy in humans.
In this study, we sought ﬁrst to test whether NIPA1 regu-
lates BMP signalling in mammalian cells. Using overexpres-
sion and depletion systems, we show that NIPA1 is an
inhibitor of BMP signalling in neuronal and non-neuronal
cells. We elucidate the mechanism of this effect by demon-
strating that the type II BMP receptor (BMPRII) is degraded
in lysosomes and that NIPA1 enhances this degradation by
physically interacting with BMPRII and promoting its endocy-
tosis and trafﬁcking to lysosomes. We also show that mutant
versions of NIPA1 are trapped in the ER, but in contrast to
previous results, we ﬁnd no increase in ER stress or induction
of UPR on expression of NIPA1 mutants. However, we show
that mutant NIPA1 does alter the trafﬁcking of BMPRII, such
that degradation of BMPRII is less efﬁcient than when only
wild-type NIPA1 is present. In addition, we show by depletion
experiments that two other endosomal HSP proteins, spastin
and spartin, are inhibitors of BMP signalling. As well as elu-
cidating molecular mechanisms that regulate mammalian
BMP receptor trafﬁcking, our results suggest that dysregula-
tion of BMP signalling could be an important unifying
mechanism causing axonopathy in the endosomal group
of HSPs.
RESULTS
NIPA1 is present on endosomes and at the plasma
membrane, where it is subject to clathrin-dependent
endocytosis
In HeLa and NSC34 (a murine hybrid neuroblastoma/motor
neuronal cell line (24)) cell lines stably expressing
NIPA1-GFP (Fig. 1A and B), we observed a predominantly
punctate/vesicular cytoplasmic localization of NIPA1. These
puncta showed partial co-localization with a number of endo-
somal pathway markers, including markers of early, late and
recycling endosomes and of lysosomes, but did not appear
to show preferential co-localization in any speciﬁc endosomal
compartment that we examined (Fig. 1C–E; Supplementary
Material, Fig. S1A–D). In NSC34 cells, the NIPA1 staining
extended into neurites (Supplementary Material, Fig. S1C).
We saw no co-localization with Golgi markers (data not
shown). In some cells weak plasma membrane staining was
seen. This plasma membrane staining was enhanced by cla-
thrin heavy chain depletion (Fig. 1F and G), indicating that
plasma membrane NIPA1-GFP is subject to clathrin-mediated
endocytosis. Our data are therefore consistent with previous
reports that endogenous NIPA1 localizes to endosomes and
to the plasma membrane in cultured mammalian cells
(19,20), but inconsistent with the additional localization of
NIPA1 to the Golgi apparatus reported by Zhao et al. (20).
NIPA1 is an inhibitor of BMP signalling in neuronal
and non-neuronal mammalian cells
We next examined whether NIPA1 regulates BMP signalling.
In the BMP signalling pathway, binding of BMP ligand to the
serine/threonine kinase BMPRII activates type I BMP recep-
tors, which in turn phosphorylate the intracellular signalling
molecules Smad 1, 5 and 8. These phosphorylated Smads
(pSmads) bind Smad 4 and then the Smad complex translo-
cates to the nucleus to regulate target gene transcription,
notably of the Id gene family (21).
We ﬁrst characterized the effect of NIPA1 overexpression
or depletion on BMPR-mediated phosphorylation of Smads
1 and 5. In a mixed stable HeLa cell line, expression of
NIPA1-GFP resulted in a diminished pSmad1/5 response to
BMP4 stimulation, compared with untransfected cells and
cells expressing another endosomal protein, GFP-Rab5
(Fig. 2A and B). Similar statistically signiﬁcant effects were
found with two clonal NIPA1-GFP HeLa cell lines (data not
shown). The attenuation of the pSmad1/5 response by
NIPA1 was slightly less than that resulting from BMPRII
knock-down (Supplementary Material, Fig. S2A). Conversely,
in HeLa cells depleted of NIPA1 using an siRNA pool of four
oligonucleotides, the concentration of pSmad1/5 signiﬁcantly
increased in unstimulated cells and showed a slight but not
signiﬁcant increase in cells stimulated with BMP4 (Fig. 2C).
A similar increase in pSmad1/5 concentration in unstimulated
cells was seen when two siRNA oligonucleotides from the
pool were used individually (Supplementary Material,
Fig. S2B), strongly suggesting that this was not an off-target
effect.
We assessed the effects of NIPA1 depletion on the
downstream BMP pathway transcriptional response by using
3806 Human Molecular Genetics, 2009, Vol. 18, No. 20a reporter gene assay with a construct containing a
BMP-responsive element derived from an Id gene promoter,
fused to the ﬁreﬂy luciferase gene (26). Results were normal-
ized against Renilla luciferase activity to control for transfec-
tion efﬁciency and cell viability. Depletion of NIPA1 using an
siRNA pool resulted in increased reporter activity in unstimu-
lated HeLa cells and cells stimulated with BMP4, compared
with control cells (Fig. 2D). Similar effects were found
when two oligonucleotides from the pool were used individu-
ally (Supplementary Material, Fig. S2C). This assay per-
formed as expected following depletion of BMPRII, which
signiﬁcantly attenuated the response to BMP stimulation (Sup-
plementary Material, Fig. S2D).
NSC34 cells are a motor neuron-derived line relevant to the
HSP phenotype and so we also used them to examine the role
of NIPA1 in BMP signalling. Since we were unable to obtain
efﬁcient siRNA-mediated knock-down of NIPA1 in this line,
we examined the effects of stable expression of NIPA1-GFP.
This lowered both the pSmad1/5 response to BMP stimulation
(Fig. 2E), and Id promoter reporter transcription (Fig. 2F) in
cells stimulated with BMP4, compared to wild-type NSC34
cells or NSC34 cells stably transfected with GFP-Rab5 (Sup-
plementary Material, Fig. S2E and F).
We concluded that NIPA1 is an inhibitor of BMP signalling
in mammalian neuronal and non-neuronal cells.
NIPA1 redistributes BMPRII from the plasma membrane
to endosomes and lysosomes
We next examined whether the inhibition of BMP signalling
caused by NIPA1 was associated with altered BMP receptor
trafﬁcking. In the Drosophila system, expression of spichthyin
results in internalization of the BMPRII receptor to an early
endosomal compartment (21). For the mammalian cell exper-
iments, we concentrated on HeLa cells to facilitate morpho-
logical examination. In transfected wild-type HeLa cells,
myc-tagged BMPRII is mainly expressed on the cell surface,
with a small amount of staining in sparse cytoplasmic vesicles.
These co-label with endogenous markers of recycling and
early endosomes, but not with late endosomes and lysosomes
(Fig. 3A and B; Supplementary Material, Fig. S3). However,
in HeLa cells stably expressing NIPA1-GFP, myc-BMPRII
was strikingly internalized from the plasma membrane and
co-localized with NIPA1-GFP not only in early and recycling
endosomes, but also in late endosomes and lysosomes (Fig. 3C
and D; Supplementary Material, Fig. S3). A similar
NIPA1-induced redistribution from the plasma membrane to
internal vesicles, including lysosomes, was observed with a
form of myc-BMPRII (myc-BMPRIIDtail) deleted for the
intracellular tail (Fig. 3E–G). Quantitation of the effect of
NIPA1-GFP indicated that 75% of total full-length myc-
BMPRII ﬂuorescence was at the plasma membrane in cells
expressing GFP alone, whereas only 25% of BMPRII ﬂuor-
escence was at the plasma membrane in cells expressing
Figure 1. NIPA1-GFP localizes to endosomes. (A) Immunoblot showing
expression of a band (arrow) of approximately the size predicted for
NIPA1-GFP (61 kDa) in the NIPA1-GFP HeLa stable cell line, but not in
similar cells transfected with pooled siRNA against NIPA1. (B) Immunoblot
showing expression of a band of approximately the size predicted for
NIPA1-GFP (arrow) in the NIPA1-GFP NSC34 stable cell line, but not in
wild-type (WT) NSC34 cells. (C–E) Stably expressed NIPA1-GFP
co-localizes in HeLa cells with early endosome antigen (EEA1; early endo-
somes; C), mannose 6-phosphate receptor (M6PR; late endosomes; D) and
Lamp1 (lysosomes; E). Although results are shown for a mixed stable cell
line, similar ﬁndings were obtained with individual clonal cell lines (data
not shown). (F and G) Clathrin heavy chain (HC) knock-down redistributed
NIPA1-GFP to the plasma membrane. (F) Control cells stably expressing
NIPA1-GFP in which mock siRNA transfections were carried out.
Minimal NIPA1-GFP or transferrin receptor (TFNR) is present at the
plasma membrane. However, when clathrin HC is depleted by siRNA knock-
down (G), TFNR was redistributed, as expected, to the plasma membrane.
NIPA1-GFP was also partially redistributed to the plasma membrane (see
inset higher magniﬁcation box). In these and subsequent micrographs, the
right-hand panels show the merged images; the colour of each marker in the
merged image is shown by the colour of its lettering in the non-merged
panels. Scale bars: 10 mm in these and subsequent micrographs.
Human Molecular Genetics, 2009, Vol. 18, No. 20 3807Figure 2. NIPA1 regulates BMP signalling. (A) A representative immunoblot examining the effect of BMP4 stimulation on the amount of pSmad1/5, in wild-
type (WT) HeLa cells or in HeLa cells stably expressing NIPA1-GFP. Immunoblotting for total Smad1 (which did not differ in concentration between WT and
NIPA1-GFP-expressing cells) is also shown. The histogram shows quantitation of pSmad1/5 immunoblot band density in ﬁve such experiments. (B) A repre-
sentative immunoblot of the effect of BMP4 stimulation on the amount of pSmad1/5, in WT HeLa cells or in HeLa cells stably expressing GFP-Rab5. The
corresponding histogram shows quantitation of pSmad1/5 immunoblot band density in three such experiments. GFP-Rab5 expression in this line was similar
to the expression level of NIPA1-GFP in the NIPA1-GFP stable line (data not shown). (C) Representative immunoblot examining the amount of pSmad1/5
and total Smad1 in HeLa cells depleted of NIPA1 by siRNA knock-down (KD) using an oligonucleotide pool, and in control cells. Results are shown for unsti-
mulated cells or cells stimulated with BMP4. The pSmad1/5 immunoblotting results of four such experiments are quantiﬁed in the corresponding histogram. (D)
3808 Human Molecular Genetics, 2009, Vol. 18, No. 20NIPA1-GFP (Fig. 3H). There was no effect on the distribution
of the epidermal growth factor receptor (EGFR) in the
NIPA1-GFP cells (Supplementary Material, Fig. S4), nor did
expression of GFP alone affect the distribution of BMPRII
compared with untransfected cells (data not shown).
In HeLa cells depleted of NIPA1, BMPRII remained predo-
minantly at the plasma membrane (data not shown). In NSC34
cells stably expressing NIPA1-GFP, the reduction of
myc-BMPRII at the plasma membrane was not as dramatic
as seen in HeLa NIPA1-GFP stable cells. Nevertheless,
expression of NIPA1 resulted in the appearance of much stron-
ger co-localization between BMPRII and lysosomes than was
seen in wild-type NSC34 cells (Fig. 4A–C). Thus, expression
of NIPA1 caused redistribution of BMPRII from the plasma
membrane to endosomal and lysosomal compartments, in
neuronal and non-neuronal cells, and this redistribution did
not depend on BMPRII tail sequences.
NIPA1 enhances lysosomal degradation
of endogenous BMPRII
We next assessed whether the NIPA1-mediated redistribution
of BMPRII to lysosomes results in increased degradation of
BMPRII. We primarily examined NSC34 cells, as a cell line
relevant to HSP. We ﬁrst showed that the inhibition of lysoso-
mal function by treatment with chloroquine (a weak base
which accumulates in endosomes and lysosomes, increasing
their pH and thus inactivating lysosomal proteases) increased
the amount of endogenous BMPRII, suggesting that BMPRII
normally undergoes signiﬁcant lysosomal degradation
(Fig. 5A). We then examined the effect of NIPA1-GFP on
endogenous BMPRII and found signiﬁcantly less in cells
stably expressing NIPA1-GFP versus wild-type cells or cells
expressing GFP-Rab5 (Fig. 5B and C). Similar effects were
seen in HeLa cells (data not shown). This effect could be
rescued by treatment with the lysosomal inhibitor chloroquine
or concanomycin A (an inhibitor of the vacuolar ATPase (27))
(Fig. 5D). Interestingly, on immunoblotting to detect endogen-
ous BMPRII, we typically saw the appearance of a higher mol-
ecular weight band in NSC34 cells stably expressing
NIPA1-GFP (Fig. 5D), suggesting that NIPA1 promotes or
stabilizes a post-translational modiﬁcation of BMPRII. In
HeLa cells this higher molecular weight band was constitu-
tively present (Supplementary Material, Fig. S2A).
We then went on to examine the effects of NIPA1 depletion
on the amount of endogenous BMPRII, using HeLa cells,
where we could efﬁciently knock-down NIPA1. We found
more BMPRII in cells depleted of NIPA1 after transfection
with pooled NIPA1 oligonucleotides (Fig. 5E). Similar
effects were seen on depletion using two individual oligonu-
cleotides from the pool, strongly suggesting that this was not
an off-target effect (Supplementary Material, Fig. S5). Thus,
overexpression and depletion of NIPA1 had converse effects.
This effect showed some speciﬁcity, since the amount of
EGFR was not altered by NIPA1-GFP expression (Sup-
plementary Material, Fig. S4). Together with the trafﬁcking
data, our results suggest that NIPA1 promotes internalization
of BMPRII and enhances its transport to lysosomes, where it
is degraded. This is likely to be the mechanism underlying
the inhibitory effect of NIPA1 on BMP signalling.
NIPA1 physically interacts with endogenous BMPRII
We next examined whether there is an interaction between
NIPA1 and BMPRII. We ﬁrst immunoprecipitated
NIPA1-GFP from NSC34 cells stably expressing the protein,
using anti-GFP, or anti-actin as a spurious control antibody,
and immunoblotted with anti-BMPRII. In samples immuno-
precipitated with anti-GFP, but not anti-actin, we observed
faint immunoblot bands corresponding to the size of
BMPRII (data not shown). In order to more clearly demon-
strate this co-immunoprecipitation, we treated the
NIPA1-GFP-expressing cells with chloroquine, to increase
BMPRII concentration. In this situation, we found clear
co-immunoprecipitation of endogenous BMPRII in cells
immunoprecipitated with anti-GFP, but not with the anti-actin
control antibody (Fig. 6A).
We examined whether the interaction between NIPA1 and
BMPRII is mediated by sequences on the cytoplasmic tail of
BMPRII by transfecting full-length myc-BMPRII or
myc-BMPRIIDtail (Fig. 3G) into HeLa cells stably expressing
NIPA1-GFP, and then immunoprecipitating as described
earlier. We did not employ chloroquine treatment in these
experiments. We found co-immunoprecipitation of both
myc-BMPRII constructs with NIPA1-GFP, but not with a
GFP-Rab5 expressing control cell line (Fig. 6B–E). Thus,
mammalian NIPA1 interacts with BMPRII, and this inter-
action is not dependent on intracellular tail sequences of
BMPRII. These results are consistent with our ﬁnding that
internalization of BMPRII from the plasma membrane to
endosomes is independent of the BMPRII cytoplasmic tail
(Fig. 3E and F).
Stable expression of mutant NIPA1 results in ER trapping
but does not provoke increased ER stress compared with
wild-type NIPA1
Reports of transient transfection experiments in mammalian
cells have indicated that mutant NIPA1 is subject to increased
ER trapping compared with wild-type NIPA1, although in at
least some published experiments this was in the context of
cells cultures showing extensive apoptotic cell death caused
The effect of NIPA1 depletion by siRNA KD using an siRNA pool on Id luciferase reporter gene activation, normalized to Renilla luciferase activity and protein
mass (n ¼ 6). (E) A representative immunoblot examining the effect of BMP4 stimulation on the amount of pSmad1/5, in WT NSC34 cells or in NSC34 cells
stably expressing NIPA1-GFP. The histogram shows quantitation of pSmad1/5 immunoblot band density in three such experiments. (F) Id luciferase reporter
gene activity, normalized to Renilla luciferase activity and protein mass, in WT NSC34 cells or in NSC34 cells stably expressing NIPA1-GFP, either unstimu-
lated or stimulated with BMP4 (n ¼ 4). (A–C and E) Actin immunoblotting veriﬁed equal loading. In all histograms, values were normalized by dividing by the
value for stimulated WT or control. Knock-down control samples were either mock-transfected or transfected with a non-targeting siRNA. Control experiments
(data not shown) demonstrated that the effect of mock-transfection or transfection with control siRNA on pSmad1/5 and id luciferase assays was identical, so
these controls were used interchangeably. Error bars: SEM. P-values were calculated using two-tailed paired t-tests.
Human Molecular Genetics, 2009, Vol. 18, No. 20 3809Figure 3. NIPA1 promotes trafﬁc of BMPRII to a lysosomal compartment in HeLa cells. Wild-type HeLa cells (A, B and E) or cells stably expressing
NIPA1-GFP (C, D and F) were transiently transfected with myc-BMPRII (A–D) or myc-BMPRIIDtail (E and F) and labelled with the early endosomal
marker EEA1 (A and C) or the lysosomal marker Lamp1 (B and D–F). In the absence of NIPA1, there is minimal co-localization between BMPRII and
EEA1 (A) and almost no co-localization between BMPRII and Lamp1 (B and E). In the cells expressing NIPA1-GFP (C, D and F), note the striking internal-
ization of both full-length and truncated BMPRII from the plasma membrane, the appearance of co-localization between NIPA1-GFP and BMPRII (which
appears yellow in the merged images) and of three-way co-localization between NIPA1, BMPRII and EEA1/Lamp1. In (A), (C), (D) and (F), arrows indicate
discrete puncta showing co-localization. (G) Schematic diagram illustrating the two N-terminal myc-tagged constructs used in experiments. The constructs
encoded either full-length BMPRII (myc-BMPRII) or a truncated form of BMPRII lacking the intracellular tail (myc-BMPRIIDtail). The transmembrane
region is shown in black, with the serine/threonine kinase domain in grey. (H) Representative experiment showing quantitation of plasma membrane
anti-myc-BMPRII ﬂuorescence versus total BMPRII ﬂuorescence, in HeLa cells transiently expressing GFP alone (32 cells), or stably expressing
NIPA1-GFP (35 cells). Error bars: SEM. P-value was calculated using unpaired t-test.
3810 Human Molecular Genetics, 2009, Vol. 18, No. 20by expression of the mutant protein (19,20). We generated
mixed stable HeLa cell lines expressing T45R or G106R
NIPA1-GFP. These cell lines maintained expression of the
mutant NIPA1-GFP well, and we did not see any evidence
of an increase in cells with apoptotic nuclei. We therefore
used these cellular models to examine whether, even in the
absence of increased cell death, mutant NIPA1 is subject to
increased ER trapping.
In both mutant lines, a proportion of cells expressed NIPA1
in a reticular pattern that co-localized with ER markers,
whereas in other cells, NIPA1 was punctate and co-localized
with endosomal markers, including EEA1, M6PR and Lamp
1. Other cells showed an overlapping pattern between these
two extremes (Fig. 7A; Supplementary Material, Fig. S6;
data not shown). The ER/reticular pattern was much more
frequent in the mutant cell lines (.40% of cells) than in the
wild-type NIPA1 line (,20% of cells). Conversely, the punc-
tate expression pattern was much less frequent in the mutant
cell lines (,20% of cells compared with .60% of cells in
the wild-type line). Our results are therefore consistent with
previous studies which showed that mutant NIPA1 is subject
to increased trapping in the ER compared with wild-type
NIPA1.
Zhao et al. (20) suggested that transient expression in mam-
malian cells of mutant NIPA1, but not wild-type NIPA1, led to
ER stress and UPR, although this was in the context of cul-
tures showing extensive cell death. We therefore examined
whether we could detect an increased ER stress response in
our stable cell lines. We assessed expression levels of
GADD34, BiP and GRP94. GADD34 is strongly induced
during ER stress, and induction of the ER chaperone BiP
has been used extensively as an indicator of the onset of
UPR (28). GRP94 is an ER chaperone which is in complex
with BiP (29). We saw no evidence of any induction of
GADD34 or GRP94 in either the wild-type or mutant cell
lines. Compared with untransfected cells, there was a trend
for BiP concentration to increase in the stable cell lines, but
this was no greater in the mutant lines than in the wild-type
NIPA1 line (Fig. 7C). As a positive control, we examined
the effect of tunicamycin on the cell lines. Correct protein
folding of many ER client proteins relies on N-linked glycosyla-
tionandexposuretotheglycosylationinhibitortunicamycinleads
toincreasedproteinmisfoldingandERstress(28).Inresponseto
tunicamycin GADD34, GRP94 and BiP were all induced to a
similar extent in untransfected cells and in the wild-type and
mutant stable lines, conﬁrming that these lines are capable of
Figure 4. NIPA1 promotes trafﬁc of BMPRII to a lysosomal compartment in neuronal cells. (A and B) Wild-type NSC34 cells (A) or NSC34 cells stably expres-
sing NIPA1-GFP (B) were transiently transfected with myc-BMPRII and labelled with the lysosomal marker Lamp1. Note the appearance of strong
co-localization between BMPRII and Lamp1 in the NIPA1-GFP-expressing cell. Arrows indicate selected individual vesicles that show co-localization. (C)
Count of vesicles doubly positive for myc-BMPRII and Lamp1 in wild-type NSC34 cells (32 cells) or stably expressing NIPA1-GFP (35 cells). Note the increase
in the number of puncta showing co-localization between Lamp1 and myc-BMPRII in the NIPA1-stable cells. Error bars: SEM. P-value was calculated using
unpaired t-test.
Human Molecular Genetics, 2009, Vol. 18, No. 20 3811showingERstressandUPR(Fig.7C).Inconclusion,wefoundno
evidence of ER stress or UPR in NIPA1 mutant cell lines, above
that seen in cells expressing wild-type NIPA1.
Mutant NIPA1 alters the trafﬁcking of BMPRII and
downregulates BMPRII less efﬁciently than wild-type
NIPA1
Since our results did not provide support for a model in which
mutant NIPA1-induced ER stress is a mechanism for the
disease, we asked whether mutant NIPA1 might differ from
wild-type NIPA1 in its role in the regulation of BMP signal-
ling or BMPRII trafﬁc.
First, we examined whether there was any abnormality of
BMP signalling in cell lines stably expressing mutant
NIPA1. We carried out pSMAD1/5 and id luciferase assays
in untransfected cells and in NSC34 cell lines stably expres-
sing wild-type or mutant NIPA1. We used motor neuron-
derived NSC34 cells to more closely reﬂect the pathological
target cells of HSP. We found that both of the mutant proteins
and the wild-type protein inhibited the response to BMP4
stimulation to a similar degree (Supplementary Material,
Fig. S7).
We next examined whether the NIPA1 mutants inﬂuenced
BMPRII trafﬁc. We began by showing that both the T45R
and G106R mutants are, like wild-type NIPA1, capable of
interacting with BMPRII in co-immunoprecipitation exper-
iments (Fig. 8A). We then determined whether the steady-state
distribution of myc-BMPRII was altered in cells expressing
mutant NIPA1. We used HeLa cells stably transfected with
NIPA1 for these assays, to facilitate examination of subcellu-
lar morphology. In cells showing an ER-like pattern of
NIPA1-mutant distribution, we found that myc-BMPRII
remained in the ER and co-localized with the mutant NIPA1
(Fig. 8B). However, in cells in which mutant NIPA1 was
present in a punctate endosomal pattern, BMPRII was also
present on the puncta (Fig. 8C). Similar results were found
for both mutants (G106R data not shown). We concluded
that if it leaves the ER, mutant NIPA1 is trafﬁcked in a
similar fashion to wild-type NIPA1 and is capable of redistri-
buting BMPRII from the cell surface to endosomes. In con-
trast, if mutant NIPA1 is trapped in the ER, it causes
retention of BMPRII there also.
We then asked whether mutant NIPA1 could downregulate
BMPRII expression level in the same way as wild-type NIPA1
did. We examined the concentration of endogenous BMPRII
Figure 5. NIPA1 enhances lysosomal degradation of BMPRII. (A) Representative experiment showing endogenous BMPRII immunoblotting in NSC34 cells
treated with the indicated amount of chloroquine. (B) Representative experiment in NSC34 cells showing the effects of stable NIPA1-GFP expression on
endogenous BMPRII. Quantitation of immunoblot band density in four such experiments is shown in the histogram. Stable expression of GFP-Rab5 did not
affect endogenous BMPRII levels, as shown in (C). (D) Representative experiment showing rescue of endogenous BMPRII levels by the lysosomal inhibitors
chloroquine (CQ) or concanamycin A (CA) in NSC34 cells stably expressing NIPA1-GFP. Note that an additional higher molecular weight band is detected by
BMPRII immunoblotting in the stable cell line. Quantitation of immunoblot band density in three such experiments is shown in the histogram. (E) Representative
immunoblot showing the effect on endogenous BMPRII of NIPA1 depletion by siRNA. The images were taken from the same immunoblot, and spurious lanes
have been spliced out. The histogram shows quantitation of BMPRII immunoblot density in three such experiments. (A, B, D and E) Actin immunoblotting
veriﬁed equal loading. In the histograms, values were normalized to the relevant wild-type or mock value. Error bars: SEM. P-values were calculated using
two-tailed paired t-tests.
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versus the cell lines expressing the T45R or G106R mutant
protein. Although downregulation of BMPRII did occur in
the mutant cell lines, it was signiﬁcantly less than that seen
in cells expressing the wild-type protein (Fig. 8D). This may
be because BMPRII reaches lysosomes less efﬁciently in the
mutant lines, either because it is sequestered in the ER by
mutant NIPA1, or because endosomal NIPA1 levels were
insufﬁcient to promote this.
We concluded that mutant NIPA1 is prone to ER trapping,
and that this can inﬂuence the trafﬁcking and degradation of
BMPRII.
Spastin and spartin are inhibitors of BMP signalling
Finally, we examined whether regulation of BMP signalling
might be a function common to other endosomal HSP proteins,
focusingonspastinandspartin.Themainpathologicalmechan-
ism associated with these proteins is loss of, or reduced, normal
function, for spastin by haploinsufﬁciency (8–11) and for
spartin by absence of the protein (13,14), so cells depleted of
the proteins are therefore appropriate disease models.
Remarkably, depletion of spastin or spartin in HeLa cells
was associated with increased pSmad1/5 concentration in
non-BMP4-stimulated cells (Fig. 9A and B) and increased Id
luciferase reporter activity in unstimulated and BMP4-
stimulated cells (Fig. 9C and D). For each protein, these
results were veriﬁed with two individual siRNA oligonucleo-
tides, strongly suggesting that they were not caused by an off-
target effect (Supplementary Material, Fig. S8). In contrast,
the use of a control non-targeting siRNA did not affect basal
pSmad1/5 levels in unstimulated cells or have any signiﬁcant
effect on the Id luciferase reporter assay, compared with mock-
transfected cells (data not shown). The effect of spastin and
spartindepletion onthepSmad andIdluciferase assaysisthere-
fore strikingly similar to that seen with NIPA1 depletion. These
results indicate that all the three of the endosomal HSP proteins
that we have tested are inhibitors of BMP signalling. However,
in the case of spastin and spartin, the mechanism of this effect
does not appear to be via regulation of BMPRII degradation,
since depletion of spastin or spartin had no effect on BMPRII
concentration (Fig. 9E).
DISCUSSION
We have found that depletion of endogenous spastin, spartin
or NIPA1 enhanced pre- and post-transcriptional BMP
Figure 6. NIPA1 co-immunoprecipitates with BMPRII. (A) NSC34 cells stably expressing NIPA1-GFP were ﬁrst treated with chloroquine to increase the con-
centration of endogenous BMPRII and used in immunoprecipitation experiments with anti-GFP, or anti-actin as a control antibody. Total cell lysates (input lane)
and the immunoprecipitated samples were then immunoblotted with anti-GFP or anti-BMPRII antibodies. The expected size of full-length endogenous BMPRII
is indicated. (B and C) HeLa cells stably expressing NIPA1-GFP and transiently transfected with either myc-BMPRII (B) or myc-BMPRIIDtail (C) were used in
immunoprecipitation experiments with anti-GFP, or anti-actin as a control antibody. Total cell lysates (input lanes) and immunoprecipitated samples were then
immunoblotted with anti-GFP or anti-myc. Immunoglobulin bands are marked ‘ ’. Control experiments in which the immunoprecipitation was carried out in cells
stably expressing GFP-Rab5 are shown on the right-hand side of (B) and (C).
Human Molecular Genetics, 2009, Vol. 18, No. 20 3813signalling, since it resulted in increased concentrations of
pSmad1/5 and increased transcriptional activity of a reporter
gene construct containing a BMP-responsive promotor. In
each case these results were veriﬁed with at least two individ-
ual siRNA oligonucleotides, indicating that they are highly
unlikely to be due to off-target effects. Remarkably, our
study therefore indicates that all three of these endosomal
HSP proteins are inhibitors of BMP signalling.
How could endosomal proteins inﬂuence BMP signalling?
In signalling pathways, there is often a close relationship
between signal transduction and endocytic membrane trafﬁc
(30–32). For many cell surface receptors, e.g. EGFR,
plasma membrane receptor levels and the consequent signal-
ling response can be regulated by sorting decisions made at
the early endosome, for example between recycling of the
receptor back to the plasma membrane, or degradation in the
lysosome (33). In addition, as well as modulating receptor
levels, endocytic processes can be important in maintaining
or attenuating the signalling response (30–32). Such a
relationship between signalling and endocytosis is known to
be important in the BMP pathway in ﬂies, where there is an
emerging recognition that endocytic processes provide a
mechanism to ﬁne-tune BMP signalling. Drosophila lacking
a number of endosomal proteins, such as spichthyin, nervous
wreck, Dap160 and spinster, show upregulated BMP signal-
ling (22,23,34). At least some of these endosomal proteins,
including spichthyin, have been implicated in regulating
endosomal BMPR trafﬁc (21,23). Thus, spichthyin binds the
Figure 7. Mutant NIPA1 is prone to ER trapping but does not induce ER stress or UPR more strongly than wild-type NIPA1. (A) When stably expressed in HeLa
cells, the T45R-NIPA1 showed an ER-like reticular distribution in some cells (left panel), a punctate distribution in others (right panel) and a mixed distribution
in a third group (middle panel). (B) Quantitation of these three distribution patterns. n ¼ 298, 312 and 310 cells of the WT NIPA1 line, the T45R mutant line and
the G106R mutant line, respectively. (C) Representative immunoblots show GADD34, BiP and GRP94 concentration in untransfected HeLa cells (UT) and HeLa
cells stably expressing wild-type (WT) or mutant forms of NIPA1-GFP, in cells treated with vehicle (DMSO) or tunicamycin. Actin immunoblotting veriﬁes
equal loading, and GFP immunoblotting veriﬁes equal expression levels of WT and mutant NIPA1-GFP in respective cell lines. (D) Histogram shows quanti-
tation of BiP expression in uninduced (i.e. no tunicamycin) samples from ﬁve such experiments. Graphed values were corrected for actin loading and then nor-
malized against the value for the untransfected (UT) samples. Error bars: SEM. P-values were calculated using two-tailed paired t-tests.
3814 Human Molecular Genetics, 2009, Vol. 18, No. 20Figure 8. Mutant NIPA1 interacts with BMPRII and alters its trafﬁcking. (A) HeLa cells stably expressing wild-type or mutant forms of NIPA1-GFP and tran-
siently transfected with myc-BMPRII were used in immunoprecipitation experiments with anti-GFP. Anti-actin was used as a control antibody in immunopre-
cipitation of the WT NIPA1-GFP sample. Total cell lysates (input lanes) and immunoprecipitated samples were then immunoblotted with anti-GFP or anti-myc.
(B and C) HeLa cells stably expressing T45R NIPA1-GFP were transiently transfected with myc-BMPRII and labelled with the ER marker calreticulin. (B) A
cell in which the mutant NIPA1, BMPRII and calreticulin show three-way co-localization. (C) A cell in which the BMPRII co-localizes with mutant NIPA1 in
perinuclear puncta. (D) Representative experiment showing the effects of stable expression of WT or mutant forms of NIPA1-GFP on endogenous BMPRII
concentration. A HeLa cell line stably expressing GFP-Rab5 was used as a control. GFP immunoblotting veriﬁed approximately equal expression levels of
GFP-tagged proteins in respective cell lines, and actin immunoblotting veriﬁed equal loading. Quantitation of immunoblot band density in four such experiments
is shown in the histogram. In the histograms, values were normalized to the value for the untransfected sample. Error bars: SEM. P-values were calculated using
two-tailed paired t-tests.
Human Molecular Genetics, 2009, Vol. 18, No. 20 3815Drosophila BMPRII, and in Drosophila S2 cells, expression of
spichthyin promotes endocytosis of BMPRII from the plasma
membrane (21), although the mechanism by which this, in
turn, downregulates BMP signalling in ﬂies is not yet clear.
In mammals, although it is known that endocytosis is
important for BMP signalling (35,36), neither the endocytic
trafﬁcking itinerary of BMPRs nor the molecular mechanisms
regulating endocytic BMPR trafﬁcking have been fully
characterized. We therefore analysed whether mammalian
NIPA1 plays a similar role to Drosophila spichthyin. We
found that NIPA1 resides on the plasma membrane and
endosomes, is an inhibitor of BMP signalling and promotes
Figure 9. Spastin and spartin are inhibitors of BMP signalling. (A) Representative experiment examining the effect of spastin siRNA knock-down (KD) using a
pool of four oligonucleotides, on the amount of pSmad1/5 in HeLa cells, in the absence or presence of BMP4 stimulation. The histogram shows quantitation of
the pSmad1/5 immunoblot band density in seven such experiments, normalized against the spastin KD value. (B) Equivalent experiments to (A), but examining
the effects of spartin depletion using spartin siRNA1 (n ¼ 4). (C) The effect of spastin KD on Id luciferase reporter gene assays, in unstimulated HeLa cells or in
cells stimulated with BMP4 (n ¼ 3). (D) An equivalent experiment to (C), but examining the effects of spartin depletion (n ¼ 5 unstimulated, n ¼ 7 stimulated).
Histogram results were normalized against the control-stimulated value. (E) Immunoblotting of BMPRII in control cells or cells depleted, by siRNA, of spastin
or spartin. Control samples were either mock-transfected or transfected with a non-targeting siRNA. Error bars: SEM. P-values were calculated using two-tailed
paired t-tests.
3816 Human Molecular Genetics, 2009, Vol. 18, No. 20internalization of BMPRII from the plasma membrane to an
endocytic compartment. In these respects, it behaves strikingly
like spichthyin. In addition, our results have given novel
insights into the mechanism by which NIPA1 regulates BMP
signalling. We have shown that the lysosome makes a signiﬁ-
cant contribution to BMPRII degradation and that NIPA1
enhances this by binding to BMPRII and promoting its
trafﬁc from the plasma membrane towards the lysosomal com-
partment. Outside of the serine/threonine kinase domain, there
is little sequence homology between the tail of mammalian
and Drosophila BMPRII (37,38), and neither binding of
NIPA1 to BMPRII nor the effect of NIPA1 in promoting endo-
cytosis of BMPRII from the plasma membrane required
sequences in the BMPRII tail. Since NIPA1 is strongly hydro-
phobic and has at least seven transmembrane regions, we
speculate that the binding between BMPRII and NIPA1 may
be mediated via a transmembrane interaction. Interestingly,
there are several transmembrane sequences that show strong
conservation between NIPA1 and spichthyin, which could be
candidate binding domains.
BMP signalling is important for axonal function. In
Drosophila, BMP signalling is a main determinant of synaptic
growth at the NMJ, and enhanced BMP signalling, for
example as found in ﬂies lacking spichthyin or the other endo-
somal proteins mentioned earlier, causes an abnormal distal
axonal overgrowth phenotype (21–23). During mammalian
development, BMP signalling regulates axonal growth, gui-
dance and differentiation (39–41); for example Id2, a
member of the Id family of BMP-responsive transcription
factors, controls axonal differentiation by regulating a
number of axonal inhibitory pathways. These include the
Nogo pathway, which is involved in the inhibition of synaptic
plasticity and the prevention of CNS axonal regeneration after
injury (41). Moreover, expression of BMPs is upregulated
after corticospinal tract injury, and the inhibition of this
upregulated BMP signalling promotes corticospinal axon
regeneration (42).
Against this background, we have found that three endoso-
mal HSP proteins are involved in the regulation of BMP sig-
nalling. Are our ﬁndings relevant to the molecular pathology
of the disease? For spastin and spartin, where haploinsufﬁ-
ciency or complete loss of the protein are pathological mech-
anisms (8–11,14), the cellular depletion assays that we
examined are pathologically relevant. Results from these
depletion experiments therefore suggest that upregulation of
BMP signalling could have a role in the development of the
phenotype. The situation is more complex with NIPA1. We
modelled the disease here by generating stable cell lines
expressing disease-associated mutants. In keeping with pre-
vious studies, we found that the mutant protein is more
prone to ER retention than the wild-type protein, and that
this retention affected BMPRII trafﬁcking. Thus, when
mutant NIPA1 was retained in the ER, BMPRII was retained
with it, whereas when mutant NIPA1 exited the ER and was
endosomal/lysosomal, so too was BMRPII. Mutant NIPA1
was less efﬁcient at promoting BMPRII degradation than wild-
type NIPA1, perhaps because BMPRII sequestered in the ER
is protected from lysosomal degradation, or because insufﬁ-
cient NIPA1 was available at endosomes to promote efﬁcient
degradation of BMPRII. However, despite the obvious effect
of mutant NIPA1 on BMPRII trafﬁc, we did not ﬁnd any
effect of expression of the mutant protein on BMP signalling
assays. The end result of expression of mutant NIPA1 on the
BMP signalling pathway is likely to be determined by an inter-
play between how much NIPA1 is retained in the ER, how
much BMPRII is retained there with it and how much
NIPA1 escapes the ER to be active in promoting BMPRII
degradation at lysosomes. An overexpression system such as
the one we used is unlikely to be able to model all of these
factors correctly, and this may explain why we did not see
any effects on BMP signalling. The development of models
expressing physiological levels of the mutant protein (e.g.
knock-in mice) will be required to fully address this issue.
Recently, Zhao et al. (20) have proposed that the molecular
pathological mechanism of NIPA1 HSP is a toxic
gain-of-function. In mammalian cells, they found that transient
transfection of mutant NIPA1 triggered ER stress and UPR,
caused by accumulation of the mutant protein in the ER.
However, their transient transfection experiments were associ-
ated with massive cell death (.90% cell death 48 h after
transfection), so it would appear that this system was highly
non-physiological. Zhao et al. also presented data to suggest
that UPR played a signiﬁcant role in a motor phenotype
seen in C. elegans overexpressing disease-associated mutant
versions of NIPA1. In contrast, we saw no evidence of
increased cell death in our stable cell lines expressing
mutant NIPA1, nor did we see any evidence of ER stress or
UPR above that seen in cell lines expressing equivalent
amounts of the wild-type protein. Thus, while not excluding
the possibility that ER stress may make a contribution to the
NIPA1-HSP phenotype, our results do not support it.
In summary, we show that three endosomal HSP proteins
are inhibitors of BMP signalling. While not excluding involve-
ment of other signalling pathways and ER stress, we propose
that upregulation of BMP signalling, caused in at least some
cases by altered endocytic BMPR trafﬁc, is an important can-
didate pathological component of the axonal degeneration
seen in the endosomal group of HSPs, and may be relevant
in other conditions showing distal axonopathy.
MATERIALS AND METHODS
Antibodies
Mouse monoclonal anti-EEA1 and anti-BMPRII were from
BD Transduction Laboratories. Mouse monoclonal anti-
Lamp1 (clone H4A3), rabbit polyclonal anti-GADD34
(C-19) and rabbit polyclonal anti-EGFR (1005; used in immu-
noblotting) were from Santa Cruz Biotechnology, Inc. Mouse
monoclonal anti-transferrin receptor was from LGC Promo-
chem. Mouse monoclonal anti-EGFR (Ab-5; used for immu-
noﬂuorescence) was from Calbiochem. Rabbit polyclonal
anti-pSmad1/5 and anti-total Smad1 were from Cell Signaling.
Mouse monoclonal anti-myc (4A6) was from Upstate Biotech-
nology, Inc. Rabbit polyclonal anti-GFP (66,57–26) was from
AbCam. Mouse monoclonal anti-KDEL (used to detect BiP
and Grp94 in immunoblotting) was from Stressgen. Rabbit
polyclonal anti-actin was from Sigma. Rabbit polyclonal
anti-M6PR and anti-spastin86–340 were as described pre-
viously (12,43). Rabbit polyclonal anti-spartin was raised
Human Molecular Genetics, 2009, Vol. 18, No. 20 3817(Harlan SeraLabs) against a GST full-length spartin-fusion
protein. Rabbit polyclonal anti-VPS26 was a kind gift of
Matthew Seaman (Cambridge), and the anti-clathrin heavy
chain was a kind gift of Margaret S. Robinson (Cambridge).
Peroxidase-conjugated secondary antibodies for western blot-
ting were obtained from Sigma. Alexaﬂuor-labelled secondary
antibodies for immunoﬂuorescence were obtained from Invi-
trogen Molecular Probes.
Constructs
The full-length cDNA for NIPA1 was ampliﬁed by PCR from
IMAGE clone 7967979 and cloned into the pEGFP-N3 vector.
The sequence of the inserts and insertion sites was veriﬁed by
sequencing (Geneservice). For production of stable cell lines,
the NIPA1-GFP coding cassette was excised from the pEGFP
vector using NheI and NotI, and then ligated into compatible
sites in the pIRESneo2 vector. Site-directed mutagenesis to
generate disease-associated mutant versions of NIPA1 was
carried out using the Phusion Site-Directed Mutagenesis Kit
(Finnzymes). The Id Fireﬂy Luciferase construct (containing
a BMP-responsive element from mouse Id1, coupled to
ﬁreﬂy luciferase) was a kind gift of P. ten Dijke (Amsterdam)
(26). Renilla luciferase vector phRL-TK(Int-) was purchased
from Promega. The Myc-BMPRII construct was based on a
pcDNA3 vector, into which a c-Myc sequence 50 to and in
frame with the coding sequence of full-length human
BMPRII was cloned.
Cell lines
The HeLa cell line used in this study was HeLaM (44). HeLa
and NSC34 (24) cells were maintained in culture as described
previously (12). Medium was supplemented with 500 mg/ml
G418 (Sigma) as a selective agent for stable cell lines.
NIPA1-GFP wild-type and mutant stable HeLa and NSC34
cell lines were made by transfecting the relevant cell type with
pIRESneo2 NIPA1-GFP constructs. Two days after transfec-
tion, transfected cells were placed under selection, by supple-
menting normal medium with G418, as described earlier.
After 2 weeks, surviving clones were trypsinized and
pooled, to constitute a stable cell line of mixed clonality,
referred to subsequently as a mixed stable cell line. The
GFP-Rab5-expressing stable cell line was a kind gift of
Matthew Seaman (Cambridge, UK). The NSC34 cell line
was a kind gift of Dr Neil Cashman (Toronto, Canada).
Transient transfection of plasmid DNA
and immunoﬂuorescence microscopy
Transient transfections of most plasmid DNA constructs were
carried out using the Effectene
w transfection reagent (Qiagen),
according to the manufacturer’s instructions and as described
previously (12,45). Following transfection, cells were incu-
bated for 24 or 48 h. Transient transfections of Id luciferase
and Renilla luciferase constructs were carried out using
HeLa Monster (Mirus) transfection reagent, according to the
manufacturer’s instructions.
Coverslips were processed for immunoﬂuorescence
microscopy as described previously (12,45). For anti-M6PR
labelling, cells were ﬁxed and permeabilized in methanol;
with other antibodies, 3.8% formaldehyde in PBS was used.
Coverslips were mounted in anti-Fade Gold medium (Invitro-
gen Molecular Probes) on a glass slide. Stained samples were
analysed on a Zeiss 510 Meta confocal microscope. Images
were recorded using LSM Image Analyzer software, and
data were subsequently processed using Adobe Photoshop
and Illustrator programs, or Volocity software (Improvision)
for quantitation of plasma membrane ﬂuorescence.
Protein depletion by siRNA knock-down
ON-TARGET or ON-TARGETplus siRNA oligonucleotides
targeting NIPA1 (catalogue numbers J-106270-05 to 08,
directed against NM_144599, termed NIPA1 siRNA1-4) were
obtained from Dharmacon and had the following sequences:
siRNA1, GCGAGGUACUUCCUAUUUAUU; siRNA2,
CCGAUGAUCUUCUCUAUAAUU; siRNA3, GUUAGAAU-
CUUUCAGGUUUUU; siRNA4, GAAUACAUGUGGCUAA-
CAAUU. An siRNA oligonucleotide to BMPRII (005309-02,
directed against NM_001204) transcripts was also obtained
from Dharmacon, Inc. Spartin siRNA oligonucleotides were
manufactured by Invitrogen and had the following sequences
obtained from (15): siRNA1, 50-GGCAAGGAUUGGAAUG
UGCAGCUAA; siRNA2, 50-CAAAUACGGAUAUAAUG
CAGGAGAAUU. Human spastin (SPG4; catalogue numbers
D-014070-01–04) individual siGENOME duplexes were
obtained from Dharmacon, Inc. and had the following
sequences: siRNA1, 50-UUAUAGAAGGUUGAAGUUCUU;
siRNA2, 50-UCAUUAUAGACGUCCGUUUUU; siRNA3,
50-UAAACUUGCAGCACUUAUAUU; siRNA4, 50-UUAG
CCAGCAUUGUCUUCCUU. Non-targeting control siRNA
(1, catalogue number D-001210-01) was obtained from Dhar-
macon, Inc. SiRNA directed against clathrin heavy chain had
the sequence UAAUCCAAUUCGAAGACCAAU, obtained
from Motley et al. (46).
A ‘double hit’ oligonucleotide transfection protocol using
oligofectamine transfection reagent (Invitrogen) was
employed for siRNA transfection, as described previously
(12), except prior to luciferase assays, where a ‘single hit’ pro-
tocol was used. NIPA1 oligonucleotides 1–4 were used in a
pool at 50 nM total concentration, or NIPA1 siRNA 1 and 2
were used individually at 50 nM. Spastin oligonucleotides 1–
4 were used either in a pool or singly, both at 5 nM total con-
centration. The BMPRII and spartin oligonucleotides were
used at 10 nM and the clathrin heavy chain oligonucleotide
at 5 nM. In the case of BMPRII, clathrin heavy chain, spastin
and spartin, protein depletion was conﬁrmed in each exper-
iment by immunoblotting using speciﬁc antibodies. Since we
did not have an NIPA1 antibody that worked in immunoblot-
ting, depletion of this protein was monitored in one of two
ways. First, we carried out siRNA transfections on HeLa
cells stably expressing NIPA1-GFP in parallel with, and
using the same pool of reagents as, the experiments on wild-
type HeLa cells. Loss of NIPA1-GFP was subsequently con-
ﬁrmed by immunoﬂuorescence or immunoblotting (Fig. 1A;
Supplementary Material, Fig. S9) and used as a reporter for
NIPA1 depletion in the wild-type cells transfected with the
same reagents. Alternatively or in addition, we used
RT–PCR to demonstrate depletion of the NIPA1 mRNA in
3818 Human Molecular Genetics, 2009, Vol. 18, No. 20wild-type HeLa cells transfected with NIPA1 siRNA. RNA
was extracted from cells using the RNeasy Kit (Qiagen),
DNAse-treated (Promega) and reverse-transcribed using
Superscript II (Invitrogen), according to the manufacturer’s
instructions. TaqMan real-time PCR for NIPA and an
endogenous control protein (hypoxanthine phosphoribosyl-
transferase 1) was then carried out in triplicate, using
TaqMan
w Gene Expression Assays (Applied Biosystems,
NIPA1: Assay ID Hs00895258_m1; hypoxanthine phosphori-
bosyltransferase 1, Assay ID Hs99999909_m1) on a Micro-
AmpTM Optical 96-Well Reaction Plate with Barcode
(Applied Biosystems). Relative RNA concentrations in the
mock- and siRNA-transfected samples were calculated using
the comparative CT method, according to the manufacturer’s
instructions (Applied Biosystems, real-time PCR system)
(Supplementary Material, Fig. S9).
pSMAD1/5 assays
Cells cultured in a six-well plate were washed with PBS and
then placed in serum-free medium overnight. In experiments
on knocked-down cells, this step happened on the day follow-
ing the second siRNA transfection. The next day, cells were
washed in PBS and placed in serum-free medium for 1 h. In
experiments involving BMP4 stimulation, this was sup-
plemented with 2 ng/ml (for NSC34 cells) or 20 ng/ml (for
HeLa cells) of BMP4 (R&D systems). Cells were washed in
ice-cold PBS, and harvested on ice in lysis buffer containing
1% Triton X-100, in the presence of a complete protease
inhibitor cocktail (Roche). Lysates were then centrifuged at
10000g for 5 min at 48C and the supernatant removed. An
aliquot of the supernatant was used to assay protein concen-
tration, determined by the Bio-Rad Protein Assay (Bio-Rad)
based on the Bradford method. The remaining supernatant
was added to 3  sodium dodecyl sulphate (SDS) sample
buffer (188 mM TRIS, 6% SDS, 30% glycerol, 0.03% bromo-
phenol blue, 10% beta-mercaptoethanol, pH 6.8). Samples
containing equivalent protein masses were heated to 988C
for 5 min before running on SDS–PAGE and subsequent
immunoblotting. For pSmad1/5 immunoblotting, membranes
were blocked in PBS with 5% powdered milk and 5%
bovine serum albumin for 3 h at room temperature, followed
by incubation overnight at 48C with the primary antibody in
5% BSA in Tris-buffered saline with 0.1% Tween (TBS-T),
then by incubation with an appropriate secondary antibody
in TBS-T containing 5% powdered milk and 5% BSA.
Labelled bands were identiﬁed using enhanced chemo-
luminescence (Amersham).
Immunoblot quantitation and statistical software
Immunoblot band density was typically quantiﬁed using a
Geldoc GS-710 densitometer and Quantity One software
(Bio-Rad). Statistical analyses and histogram construction
were carried out in GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego, CA, USA). Quan-
titation of BiP immunoblot density was carried out using ﬂu-
orescent secondary antibodies and a TyphoonTM 9410
Variable Mode Imager (GE Healthcare, Amersham, UK),
according to the manufacturer’s instructions.
Inhibition of lysosomal function
Cells were ﬁrst grown to the desired conﬂuency in six-well
plates. They were then washed in PBS, and fresh medium
was added, supplemented with chloroquine (10 mM) or conca-
namycin A (5 nM) for 8 h, before being harvested into chilled
lysis buffer containing 1% Triton X-100, as described earlier.
Luciferase assays
Id Fireﬂy luciferase and Renilla luciferase constructs (3 and
0.3 mg DNA, respectively) were transfected using HeLa
Monster transfection reagent (Mirus). In experiments on
knocked-down cells, this was done on the day following trans-
fection with the relevant siRNA. Cells were placed in a serum-
free medium for the ﬁnal 24 h of the DNA transfection, and in
experiments involving BMP4 stimulation, this was sup-
plemented with 2 (for NSC34 cells) or 20 ng/ml (for HeLa
cells) of BMP4 (R&D systems). Fireﬂy and Renilla luciferase
activities were then assayed in duplicate using the Promega
Dual Luciferase Assay Kit, with a Promega Glomax lumin-
ometer, according to the manufacturer’s instructions. Fireﬂy
luciferase activity was corrected for transfection efﬁciency
and cell viability by dividing by Renilla luciferase activity,
and then the results were expressed per microgram of lysate
protein.
Co-immunoprecipitation
In experiments involving co-immunoprecipitation of exogen-
ous myc-BMPRII and NIPA1-GFP, HeLa cells stably
expressing NIPA1-GFP were plated out into two 10 cm
dishes at 50% conﬂuence and then transfected with the
relevant myc-BMPRII construct, with Effectene
w transfection
reagent, using 3 mg of vector DNA per dish. At 48 h post-
transfection, cells were harvested with ice-cold digitonin
lysis buffer (0.1 M MES NaOH pH6.5, 1 mM Mg acetate,
0.5 mM EGTA, 200 mM Na orthovanadate, 1% digitonin) con-
taining complete protease inhibitors (Roche). A soluble frac-
tion was then obtained by retaining the supernatant after
centrifugation at 10 000g for 5 min at 48C. Subsequent proces-
sing was carried out as described previously (45,47).
Co-immunoprecipitates were suspended in 3  SDS sample
buffer and then run on SDS–PAGE and immunoblotted with
appropriate antibodies.
For co-immunoprecipitation of endogenous BMPRII with
NIPA1-GFP, NSC34 cells stably expressing NIPA-GFP were
plated out, then lysed and subsequently processed in the
same way as described earlier. In some cases, the cells were
treated with concanamycin A before lysis, as described earlier.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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